← Evidence map

ArticleViruses2025

Genomic Evolution of SARS-CoV-2 Variants of Concern Under In Vitro Neutralising Selection Pressure Following Two Doses of the Pfizer-BioNTech BNT162b2 COVID-19 Vaccine.

Kerri Basile et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Genomic Evolution of SARS-CoV-2 Variants of Concern Under In Vitro Neutralising Selection Pressure Following Two Doses of the Pfizer-BioNTech BNT162b2 COVID-19 Vaccine. | OpenQuestion